Inject subcutaneously on an empty stomach, 23x daily, with the bedtime dose most important
It is often best to start with a lower dose and slowly increase it
[Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] [Crossref] [Google Scholar] [PubMed] Citation: Arumugam A, Lakshmi G, Gopineedu S, Rao N (2024)
Summary Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world
While these reports align with clinical trial observations, it's important to distinguish between temporal association (events occurring around the same time) and true causality, which requires rigorous investigation
There are studies showing that patients who experience more robust weight loss after MBS have higher levels of GLP-1 as compared with patients who have less favorable weight loss [12, 13, 24,25,26,27,28]